Effect of tamoxifen on measurements of hemostasis in healthy women

Archives of Internal Medicine

Volumn 156, Issue 16, 1996, Pages 1806-1810

  Mannucci, P M ^a,b,c   Bettega, D ^a,b   Chantarangkul, V ^a,b   Tripodi, A ^a,b   Sacchini, V ^b   Veronesi, U ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PREVENTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; FEMALE; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HEMOSTASIS; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOSIS;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BLOOD CELL COUNT; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; ESTROGEN ANTAGONISTS; FEMALE; FIBRINOLYSIS; HUMANS; HYSTERECTOMY; LIPIDS; MIDDLE AGED; REFERENCE VALUES; TAMOXIFEN;

EID: 0029791115     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.16.1806     Document Type: Article

References (21)

1. Bonadonna G, Valagussa P, Brambilla C, Moliterni A, Zambitti M, Ferrari LS. Adjuvant and neoadjuvant treatment of breast cancers with chemotherapy and endocrine therapy. Semin Oncol. 1991;18:515-524.
2. Early Breast Cancer Trials Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, and immune therapy: 133 randomized trials involving 33000 recoveries and 24000 deaths among 75000 women. Lancet. 1992;399:1-15.
3. Fornander T, Rutqvist IE, Cedermark B, et al. Adjuvant tamoxifen in early breast cancer occurrence of new primary cancer. Lancet. 1989;1:117-120.
4. Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen PJ, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol. 1993;81:660-664.
5. Moursiden H, Palshof T, Petterson J, Battersby L. Tamoxifen in advanced breast cancer. Cancer Treat Rev. 1978;5:131-141.
6. Love RR. Tamoxifen therapy in primary breast cancer: biology, efficacy and side effects. J Clin Oncol. 1989;7:803-815.
7. Nevasaari K, Heikkinen M, Taskinen PJ. Tamoxifen and thrombosis. Lancet. 1978;2:946-947.
8. Hendrick A, Subramanian VP. Tamoxifen and thromboembolism. JAMA. 1980; 243:514-515.
9. Lipton A, Harvey HA, Hamilton RW. Venous thrombosis as a side eftect of tamoxifen treatment. Cancer Treat Rep. 1984;68:887-889.
10. Dahan R, Espie M, Mignot L, Houlbert D, Chanu B. Tamoxifen and arterial thrombosis. Lancet. 1985;1:638.
11. Katzenellenbogen BS, Norman MJ, Eckert RL, Peltz SW, Mangel WF. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxytamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res. 1984;44:112-119.
12. Caine YC, Bauer KA, Barzegar S, et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost. 1992;68: 392-395.
13. Nabulsi AA, Folsom AR, White A, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med. 1993;328:1069-1075.
14. Auger MJ, Mackie MJ. Effects of tamoxifen on blood coagulation. Cancer. 1988; 61:1316-1319.
15. Powles TJ, Hardy JR, Ashley SE, et al. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer. 1989;60:126-131.
16. Love RR, Surawicz TS, Williams EC. Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy. Arch Intern Med. 1992;152:317-320.
17. Pemberton KD, Melissari, Kakkar VV. The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis. Blood Coagul Fibrinolysis. 1993; 4:935-942.
18. Bauer KA, Rosenberg RD. Activation markers of coagulation. In: Meade TW, ed. Balliere's Clinical Hematology: Thrombophilia. London, England: Balliere Tindall; 1994;7:523-542.
19. Meade TW. Haemostatic function, arterial disease and the prevention of arterial thrombosis. In: Meade TW, ed. Balliere's Clinical Hematology: Thrombophilia. London, England: Balliere Tindall; 1994;7:733-757.
20. Cooper DN. The molecular genetics of familial venous thrombosis. In: Meade TW, ed. Balliere's Clinical Hematology: Thrombophilia. London, England: Balliere Tindall; 1994;7:637-674.
21. Woodhause PR, Khaw K-T, Plummer M, Foley A, Meade TW. Seasonal variation of plasma fibrinogen and factor VIII activity in an elderly population and the relationship of fibrinogen to winter infections. Lancet. 1994;343:435-439.